Literature DB >> 3954494

Somatosensory evoked potentials in the detection of spinal cord ischemia in aortic coarctation repair.

J C Pollock, M P Jamieson, R McWilliam.   

Abstract

Cortical somatosensory evoked potential (SEP) monitoring was used in 15 patients 2 to 50 years old undergoing repair of aortic coarctation to detect the onset of spinal cord ischemia during the cross-clamp period. Three different response patterns were observed. In 8 patients (53%), the SEP remained unchanged throughout the cross-clamping. This was designated a type 1 response. Six patients (40%) showed a gradual deterioration in the SEP after 15 minutes of cross-clamping (type 2 response). All SEPs returned to normal levels within 5 minutes of release of the clamp. One patient (7%) demonstrated a decline in SEP commencing prior to the application of the cross-clamp when an intercostal vessel was controlled with slings. The SEP completely disappeared within 5 minutes of cross-clamping, but after 19 minutes the repair was completed and the SEP returned within 3 minutes of reperfusion (type 3 response). No patient sustained neurological sequelae of repair. We believe that SEP monitoring offers the potential to identify the patient at risk of developing spinal cord ischemia intraoperatively before irreversible damage occurs. However, it is susceptible to deep halothane anesthesia, which abolishes all cortical responses and requires expert monitoring.

Entities:  

Mesh:

Year:  1986        PMID: 3954494     DOI: 10.1016/s0003-4975(10)62764-6

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  2 in total

1.  Intraoperative somatosensory evoked responses recorded during onset of the anterior spinal artery syndrome.

Authors:  M H Zornow; J C Drummond
Journal:  J Clin Monit       Date:  1989-10

2.  Spinal cord damage and operations for coarctation of the aorta: aetiology, practice, and prospects.

Authors:  G Keen
Journal:  Thorax       Date:  1987-01       Impact factor: 9.139

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.